Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

SHIONOGI B.V.

Home Clinical Trial Sponsors and OrganizationsSHIONOGI B.V.

SHIONOGI B.V.

50 EASTBOURNE TERRACE, London, United Kingdom

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

28

19 active

Approvals

11

Total approvals

Agencies

2

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

25

89.3%

Phase 2

3

10.7%

Trial Status Distribution

Active, not recruiting

19

67.9%

Completed

5

17.9%

Recruiting

3

10.7%

Withdrawn

1

3.6%

Clinical Trials

Trials sponsored by this organization (28)

A pharmacokinetics and safety study of cefiderocol in hospitalized pediatric patients from birth to less than 3 months of age with suspected or confirmed Gram-negative bacterial infections

Active, not recruiting

Jun 202340 participants

A phase 2b, randomized, double-blind study of redasemtide (S-005151) in adult participants with acute ischemic stroke

Mar 2023524 participants

Phase I Trial, Quotient Code: QSC207970

Feb 20236 participants

Clinical research study to assess if naldemedine is safe and tolerable whenadmininstered to paediatric patients (patients under the age of 18) whoare receiving or about to receive treatment with a class of drugs called opioids

Active, not recruiting

Dec 202224 participants

Phase I Trial, Quotient Code: QSC206367

Jul 20226 participants

Phase I Trial, Quotient Code: QSC206321

Jun 20226 participants

Study of cefiderocol or standard of care for paediatric patients with confirmed or suspected Gram-negative bacterial infections receiving a single dose and paediatric patents with confirmed or suspected complicated urinary tract infections receiving multiple doses to assess the safety, tolerability and exposure of cefiderocol.

Active, not recruiting

Sep 202085 participants

Mass Balance Study of [14C]-S-600918 Oral Suspension in Healthy Male Subjects

Jul 20206 participants

Page 1 of 4

Approvals

Approvals by Agency

EMA

European Medicines Agency

7

Approvals

CIMA_AEMPS

Spanish Agency for Medicines and Medical Devices

4

Approvals

Recent Approvals

FETCROJA 1 G POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION

MULPLEO 3 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

RIZMOIC 200 MICROGRAMOS COMPRIMIDOS RECUBIERTOS CON PELICULA

Mulpleo (previously Lusutrombopag Shionogi)

SENSHIO 60 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

News

No news articles found

On this page

Overview
Clinical Trials28
Approvals11
News

Back to Organizations